Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AstraZeneca PLC
Pfizer is up against AstraZeneca and Sanofi in developing competing approaches to tackling the unmet need in respiratory syncytial virus (RSV). But earlier failures mean all players will need much more data to sway regulators.
Concern and skepticism about Russia's rapid vaccine roll out. Meanwhile Japan is latest to reach deal with Pfizer/BioNTech.
Pink Sheet Podcast: Coronavirus Vaccines Move Into Phase III, US FDA Coronavirus Workload Changes, Rare Pediatric Priority Review Voucher Expiration
Pink Sheet reporters and editor discuss the start of Phase III coronavirus vaccine trials, FDA’s pandemic work is transitioning away from the idea stage, and the push for a permanent extension of the rare pediatric disease priority review voucher program.
The expectation of a big second quarter sales decline proved true, but the situation is improving. Meanwhile, Merck & Co. is advancing two vaccines and an antiviral against the novel coronavirus.
- Other Names / Subsidiaries
- Almirall Sofotec
- AlphaCore Pharma
- Amplimmune, Inc.
- Ardea Biosciences, Inc.
- Arrow Therapeutics
- Cellective Therapeutics, Inc.
- IntraBiotics Pharmaceuticals, Inc.
- KuDOS Pharmaceuticals Ltd.
- Omthera Pharmaceuticals
- Pearl Therapeutics
- Spirogen Ltd.
- U.S. Bioscience
- Acerta Pharma
- ZS Pharma